Pharmerica Corporation (PMC)

Get PMC Alerts
*Delayed - data as of May 22, 2015  -  Find a broker to begin trading PMC now
Exchange: NYSE
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

PharMerica Corporation (PMC)

Q1 2014 Earnings Conference Call

May 2, 2014 10:00 ET


Cynthia Archer - Manager, Treasury and Risk

Greg Weishar - Chief Executive Officer

David Froesel - Executive Vice President, Chief Financial Officer and Treasurer


Glen Santangelo - Credit Suisse

Jason Gurda - KeyBanc

Brendan Strong - Barclays

Frank Morgan - RBC Capital Markets

Robert Willoughby - Bank of America/Merrill Lynch



Good day, ladies and gentlemen and welcome to the Quarter One 2014 PharMerica Corporation Earnings Conference Call. My name is Julian, and I will be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of the conference. (Operator Instructions) As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Ms. Cynthia Archer. Please proceed, ma’am.

Cynthia Archer

Good morning and thank you for joining us for the first quarter 2014 conference call. On the call with me today are Greg Weishar, Chief Executive Officer; and David Froesel, Executive Vice President, Chief Financial Officer and Treasurer.

Before beginning our remarks regarding the first quarter 2014 results, I would like to make a cautionary statement. During the call today, we will make forward-looking statements about our business prospects and financial expectations. We want to remind you that there are many risks and uncertainties that could cause our actual results to differ materially from our current expectations.

In addition to the risks and uncertainties discussed on this morning’s press release and in the comments made during this conference call, more detailed information about the additional risks and uncertainties may be found in our SEC filings including our annual report on Form 10-K and quarterly report on Form 10-Q. Copies of these documents maybe obtained from the SEC or by visiting the Investor Relations section of our website. PharMerica assumes no obligation to update the matters discussed on this call.

During this call, we will be referring to non-GAAP financial measures. These non-GAAP measures are not prepared in accordance with Generally Accepted Accounting Principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release and in our quarterly report on Form 10-Q. We have made available to you our press release and our quarterly report on Form 10-Q filed with the SEC. In addition, this webcast will be on our website along with the transcript from this call.

And now at this time, I would like to turn the call over to Greg.

Greg Weishar

Thank you, Cynthia and thanks for all of you. As always, we appreciate for your attendance and your interest in PharMerica.

As you saw in this morning’s earnings release, we have reported strong results. Revenue, adjusted EBITDA and adjusted diluted earnings per share, all exceeded expectations for the first quarter. These results demonstrate the company is off to a great start towards achieving stated 2014 objectives and long-term growth and value creation.

Let me summarize the highlights. Excluding Golden Living and Kindred, we posted another sequential quarter of organic growth. This gives us confidence that we are gaining competitive strength in the core long-term care business. We anticipate achieving net organic bed growth for the year. The strategic investment in Onco360 in December 2013 gives us market entry into the large and fast growing specialty oncology pharmacy market. Growth in revenues on a year-over-year and sequential basis was in large part due to the inclusion of 100% of Onco360’s revenues in the first quarter of 2014. Amerita continues to grow according to plan. Amerita also achieved record revenues.

We continue to bring value to our clients through an industry-leading generic dispensing rate. The generic dispensing rate for the quarter was 84.5%, an improvement of 120 basis points year-over-year and 80 basis points sequentially. Looking towards the end of 2015, the generic dispensing rate is forecasted to hit 88% due to upcoming patent expirations. Nexium, Namenda and Abilify lead the list.

The investment in Onco360 coupled with the acquisition of Amerita reflects our focus on pursuing diversified growth opportunities in closely-related pharmacy markets. We believe the specialty infusion and oncology businesses will generate revenues of approximately $400 million by 2016. Complementing organic growth initiatives, we have a stated goal to complete acquisitions yearly that generate at least $100 million of annualized sales. We are targeting companies in the institutional pharmacy and specialty infusion pharmacy markets. And we are evaluating a number of acquisition opportunities and are optimistic we will achieve our yearly goal.

So, with that, I will turn it over to Dave. He will walk you through the financials.

David Froesel

Thank you, Greg and good morning. I would like to spend the next several minutes discussing our results of operations for the first quarter of 2014. Revenues reported for the first quarter of 2014 were $452.2 million, which represents an increase of $12.4 million or approximately 3% versus the first quarter of 2013. In addition, on a sequential basis, revenues were slightly higher. The increase in revenues on a year-over-year basis was primarily attributable to PharMerica’s new investment in Onco360, strong branded drug inflation and growth in our specialty home infusion business, Amerita. More importantly, revenues associated with Onco360, home infusion and branded drug inflation more than offset losses in revenues associated with Kindred and Golden Living.

Gross profit for the quarter was $80 million or 17.7% of revenues as compared to $84.3 million or 19.2% of revenues in the comparable quarter of last year. The decrease in gross profit was primarily associated with the loss of Kindred and Golden Living facilities partially offset by lower cost associated with our planned restructuring program and improved drug purchasing economics. In addition, the Onco360 business contributed to gross profit dollars in the current quarter. On a gross profit dollar per script basis, Onco360 metrics are higher than PharMerica’ institutional pharmacy business, however, lower on a gross profit percentage of revenue basis.

Read the rest of this transcript for free on